FORWARD WATER TECHNOLOGIES CORP. (Formerly Hope Well Capital Corp.) Management's Discussion and Analysis

For the years ended March 31, 2022 and 2021

The date of this management's discussion and analysis ("MD&A") is July 11, 2022.

The following MD&A should be read in conjunction with the financial statements of Forward Water Technologies Corp ("FWT" or the "Company") for the years ended March 31, 2022 and 2021, prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

Forward-Looking Statements and Future-Oriented Financial Information

This MD&A contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, which reflect management's expectations regarding the Company's future growth, results from operations (including, without limitation, future production and capital expenditures), performance (both operational and financial) and business prospects, future business plans and opportunities. Wherever possible, words such as "predicts", "projects", "targets", "plans", "expects", "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements.

Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management, in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances. Forward-looking Statements in this MD&A include, without limitation, statements with respect to:

- continued use of the Company's services, sources of the Company's revenue;
- the incurrence of legal fees in relation to defending any civil proceedings involving Company;
- the ability of the Company to continue as a going-concern;
- the effect of a change of control on the Company's material contracts,
- the Company's dependence on key personnel;
- the Company's ability to achieve or maintain profitability;
- the ability of clients terminating contracts with the Company and the impact thereof;
- ongoing costs and obligations of the Company;
- the Company's need and ability to obtain additional financing;
- the Company's ability and intention to develop intellectual property and the Company's dependence on suppliers and skilled labour;
- growth-related risks such as capacity constraints and pressure on internal systems and controls;
- the likelihood of reputational harm to the Company and the impact thereof; and
- the impact of pandemics, including COVID-19, on the Company, applicable regulation, and global commerce.

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

Important factors that could cause actual results to differ materially from the Company's expectations include, without limitation:

- clients deciding to terminate contractual relationships with the Company;
- the potential for adverse or positive tax judgments in the jurisdictions in which the Company operates or changes to applicable tax rules in such jurisdictions;
- market conditions;
- the potential for adverse or positive judgments with respect to any civil proceedings involving the Company;
- the departure of key personnel or other employees of the Company;
- changes in technology, customer preferences, or supply chains;
- changes in accounting policies or procedures applicable to the Company's assets;
- the exacerbation of the COVID-19 pandemic;
- and other risk factors set forth in this MD&A.

While we consider the assumptions used in making these forward looking statements to be reasonable, the assumptions are inherently subject to significant business, social, privacy, economic, political, regulatory, competitive and other risks, uncertainties, contingencies and other factors that could cause actual actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Many assumptions are based on factors and events that are not within our control and there is no assurance they will prove to be correct.

Furthermore, such forward-looking statements involve a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of the Company to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements.

Although we have attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, conditions, results, or performance achievements to differ from those anticipated, estimated or intended.

Readers are cautioned that the list of assumptions and risks, uncertainties and other factors contained herein are not exhaustive. Other events or circumstances could cause actual results to differ materially from those estimated or projected and expressed in, or implied by, the forward-looking information contained herein. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking statements.

Forward-looking statements contained herein are made as of the date of this MD&A and we disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as and to the extent required by applicable securities laws. The MD&A is a narrative explanation, through the eyes of management, of how FWT and its operating subsidiary performed during the period covered by the financial statements, and of FWT's financial condition and future prospects. The MD&A complements and supplements FWT's financial statements but does not form part of FWT's financial statements.

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

Unless otherwise indicated, all dollar amounts are expressed in Canadian dollars (CAD). Due to rounding, certain totals, subtotals and percentages may not reconcile.

Major Highlights for Year Ending March 31, 2022

- On October 20, 2021 the Company completed a qualifying transaction (the "Transaction") under the rules of the TSX Venture Exchange (the "Exchange") with Forward Water Technologies Inc ("FWTI")
- The Transaction constituted a reverse acquisition in accordance with IFRS as the shareholders of FWTI took control of FWT (Hope Well Capital Corp ("HWCC"))
- On November 4, 2021, the Company was listed on the Exchange under the symbol "FWTC"
- In connection with the Transaction, FWTI completed a brokered private placement offering of an aggregate of 6,470,000 subscription receipts ("Subscription Receipts") at a subscription price of \$1.00 per Subscription Receipt for aggregate gross proceeds of \$6,470,000
- In December 2021, FWTC began the building of a mobile commercial demonstration unit which
 can be placed on a customer's site to allow for a longer term (3-4 month) performance of the
 Company's forward osmosis technology. This is expected to be completed in July 2022 at a cost
 of \$1.1 million
- As a result of successful financing, FWTC executed on its staffing plans. Grant Thornley was hired as the VP of Engineering Sales as of October, 2022 and Alessandra Rodrigues who was on short term contract was converted to full time as Laboratory Manager and Research Engineer. Mr. Thornley bring years of sales and marketing experience in the water treatment industry including experience at Xenon and Fibracast. FWTC also confirmed that it has renewed its contract with Mr Leonard Seed to serve as Director of Engineering and Operations

Major Highlight Subsequent to March 31, 2022

 On May 4, 2022, FWTC entered into an agreement with Cornish Lithium Ltd to fund trials of the Company's FO technology on Cornish geothermal waters. This follows favourable initial results, which demonstrated the potential of the Company's technology to increase lithium concentrations of Cornish geothermal waters.

Overview

The Company was incorporated under the laws of the Province of Ontario on December 1, 2016 and its operating subsidiary is FWTI. FWTI is a corporation incorporated pursuant to the laws of the Province of Ontario on October 11, 2012 dedicated to the commercialization of its proprietary forward osmosis technology. The technology allows businesses to clean their wastewater that would otherwise require costly disposal. The technology also enables the reclamation of up to 90% of the waste as clean water and the return of this valuable resource to the environment. Alternatively, the clean water can be reused by manufacturing operations to reduce a customer's overall water consumption and environmental footprint.

FWT extracts clean water through a membrane utilizing a Forward Osmosis (FO) method. Without using applied pressure, applied energy, or forced filtration FWT's FO process rejects all impurities and separates

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

only the clean water from the waste stream. The Company has now completed full commercial design of modular transportable containerized equipment and is prepared to deliver this equipment to end users.

FWT is targeting three sectors:

- a) Industrial wastewater: to divert hazardous waste disposal currently transported and injected into wells or incinerated.
- b) Brine Management: the concentration of brines where the dissolved materials in the brine or the concentrated brines themselves have value. For example, the concentration of brines containing valuable minerals such as lithium become easier to process leading to a lower cost of recovery.
- c) Food and beverage: to manufacture product concentrates, water is removed through the passive filtering process which is vastly superior to thermal concentrates that erode the flavor and aroma components due to excessive heating. Target products are in fruit juices, alcoholic beverages such as beer and wines, coffee and teas, herbal extracts, and nut milks.

FWT has developed three revenue models:

- a) Build Own Operate: FWT constructs a facility for on-site operation and operates the equipment as a service. Customer pays a fee for each cubic meter of wastewater treated.
- b) Build Operate Transfer: FWT constructs a facility for on-site operation and operates the equipment as a service. Over time, and pursuant to service contract and purchase agreements, operations are taken over by customer. Service and maintenance contracts will continue post-transfer.
- c) Licensing: Addressing foreign markets FWT intends to license the technology with well-established equipment providers and operators. It is anticipated that this will generate transfer fees and ongoing royalties.

Reverse takeover transaction (the "Transaction")

On October 20, 2021, HWCC completed the Transaction with FWTI.

The Transaction was completed by way of a three-cornered amalgamation pursuant to the provisions of the *Business Corporations Act* (Ontario), whereby 2644246 Ontario Limited, a wholly-owned subsidiary of HWCC, amalgamated with and into FWTI, with FWTI surviving as a wholly-owned subsidiary of HWCC. Pursuant to the Transaction, the outstanding common shares and warrants of FWTI were exchanged for common shares and warrants, respectively, of HWCC on the basis of five HWCC securities for every one FWTI security (the "Exchange Ratio"). Immediately following the completion of the Transaction, HWCC changed its name from "Hope Well Capital Corp." to "Forward Water Technologies Corp.".

In connection with the Transaction, FWTI completed a brokered private placement offering of an aggregate of 6,470,000 subscription receipts ("Subscription Receipts") at a subscription price of \$1.00 per Subscription Receipt for aggregate gross proceeds of \$6,470,000. At closing of the Transaction, each Subscription Receipt was converted, for no additional consideration, into one unit of FWTI (a "FWTI Unit"). Each FWTI Unit consisted of one common share in the capital of FWTI and one-half of one common share purchase warrant, with each whole warrant entitling the holder thereof to acquire one FWTI common share at an exercise price of \$1.25 for 24 months following the closing of the Transaction, subject to adjustment and

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

acceleration. Each FWTI common share and FWTI common share purchase warrant issued pursuant to the conversion of the Subscription Receipts was exchanged for common shares and warrants, respectively, of HWCC on the basis of five HWCC securities for every one FWTI security and the exercise price of the warrants was adjusted to \$0.25.

Immediately prior to the closing of the Transaction, two series of FWTI convertible debentures were converted into 1,652,380 FWTI common shares, which were exchanged for the shares of the Company based on the Exchange Ratio.

Immediately following the closing of the Transaction, there were 105,600,099 common shares of the Company outstanding, of which 97,875,100 were held by the former shareholders of FWTI (representing approximately 92.7% of the outstanding shares of the Company) and 7,724,999 (7.3%) were held by the shareholders of HWCC. As the former shareholders of FWTI, as a group, retained control of the resulting issuer, FWTC. The Transaction was accounted for as a reverse acquisition where FWTI is deemed to be the acquirer for accounting purposes. The audited consolidated financial statements for the years ended March 31, 2022 and 2021 to which this MD&A relates represent the continuance of FWTI and reflect the identifiable assets acquired and liabilities assumed of HWCC at fair value. The results of operations of HWCC have been included in the consolidated statements of comprehensive loss from October 20, 2021, the closing date of the Transaction.

As HWCC did not meet the definition of a business as defined in IFRS 3 – Business Combinations, the acquisition was not within the scope of IFRS 3 and is accounted for as a share-based payment transaction in accordance with IFRS 2, Share-based Payments. Accordingly, the fair value of the purchase consideration was accounted for at the fair value of the equity instruments deemed issued by the shareholders of FWTI to the shareholders and option holders of HWCC. The fair value of the shares was determined based on the historical trading price of HWCC which was determined to be the most reliable measure of the Transaction. The fair value of the options was determined using the Black-Scholes pricing model.

The consideration for the Transaction has been calculated as \$1,598,901 and is based on the fair value of the number of shares and options that were issued to the shareholders and option holders of HWCC to give the shareholders and option holders of HWCC the same percentage equity interest in the combined entity that resulted from the Transaction. The following table summarizes the allocation of the purchase price consideration to the fair value of the net assets acquired at October 20, 2021, the closing date of the Transaction.

Purchase consideration	
Fair value of deemed issuance of FWTI shares	\$ 1,545,000
Fair value of deemed issuance of FWTI options	53,901
Fair value of consideration	1,598,901
Identifiable assets acquired	
Cash	455,420
Net assets acquired	455,420
Listing expense	1,143,481
	\$ 1,598,901

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

In addition to the above-mentioned listing expense, the Company incurred \$505,128 in legal and accounting fees in connection with the Transaction. Further, the agent involved in the offering of the Subscription Receipts received a cash finder's fee of \$165,480 and 220,640 units (the "Finder Units") for a total fair value of \$386,120.

Each Finder Unit was comprised of one common share in the capital of FWTI and one-half of one common share purchase warrant, with each whole warrant entitling the holder thereof to acquire one FWTI common share at an exercise price of \$1.25 for 24 months. In connection with the closing of the Transaction the securities underlying the Finders Units were exchanged for securities of the Company based on the Exchange Ratio and the exercise price of the warrants was adjusted to \$0.25.

Share capital:

	# Shares*	Amount
Balance at March 31, 2021 & 2020	54,000,000	\$ 1,636,352
Exercise of warrants	1,160,000	230,880
Shares issued in relation to private placement net of issue costs	32,350,000	4,058,108
Advisory shares issued	1,000,000	200,000
Shares issued in reverse takeover	7,724,999	1,545,000
Shares issued for services (Finder's fee)	1,103,200	174,306
Conversion of convertible debenture	8,261,900	1,652,380
Balance at March 31, 2022	105,600,099	\$ 9,497,026

^{*}All figures reflect the Exchange Ratio

(a) As referenced in the table above, in connection with the Transaction, FWTI completed the first tranche of a brokered private placement offering for an aggregate of 5,170,000 Subscription Receipts at a subscription price of \$1.00 per Subscription Receipt on June 4, 2021 and the second tranche of 1,300,000 Subscription Receipts on the same terms on July 26, 2021, resulting in aggregate gross proceeds of \$6,470,000. Immediately prior to the closing of the Transaction, each Subscription Receipt was converted, for no additional consideration, into one unit of FWTI (a "FWTU Unit"). Each FWTI Unit consisted of one common share in the capital of FWTI and one-half of one common share purchase warrant, with each whole warrant entitling the holder thereof to acquire one FWTI common share at an exercise price of \$1.25 for 24 months following the Transaction, subject to adjustment and acceleration. Each FWTI common share and FWTI common share purchase warrant issued pursuant to the conversion of the Subscription Receipts was exchanged for common shares and warrants, respectively, of the Company on the basis the Exchange Ratio and the exercise price of the warrants was adjusted to \$0.25.

The allocation of the FWTI Unit between share capital and warrants was done based on the relative fair value of each of the components after applying the Exchange Ratio. The securities underlying FWTI Units were converted at the Exchange Ratio at the closing of the Transaction, and as a result their fair value has been determined based on the value of the HWCC (Resulting Issuer) shares as

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

that was determined to represent the most reliable measure of the share consideration. The fair value of the share capital was determined to be \$0.20. The fair value of the warrants was determined using the Black-Scholes pricing model.

The relative fair value of the shares was determined to be \$5,111,300 and the relative fair value of the warrants was determined to be \$1,358,700.

In connection with the private placement of Subscription Receipts, FWTI issued 343,600 broker warrants ("QT Broker Warrants") on June 4, 2021 and 34,000 QT Broker Warrants on July 26, 2021, with each QT Broker Warrant being exercisable for one underlying unit (a "QT Broker Unit") at a price of \$1.00 for a period of 24 months from the closing date of the Transaction. The QT Broker Units were comprised of one FWTI Share and one-half of one FWTI common share purchase warrant, with each such warrant entitling the holder thereof to purchase one common share in the capital of FWTI at a price of \$1.25 for a period of 24 months following the closing date of the Transaction, subject to adjustment in certain events. The warrants are governed by a warrant indenture. The QT Broker Units were converted at the Exchange Ratio at the closing of the Transaction, and their fair value was determined based on the value of the HWCC (Resulting Issuer) shares as that was determined to represent the most reliable measure of the share consideration.

The fair value of 343,600 QT Broker Warrants issued on June 4, 2021 was determined to be \$211,832 using the Black-Scholes pricing model.

The fair value of 34,000 QT Broker Warrants issued on July 26, 2021 was determined to be \$20,999 using the Black-Scholes pricing model.

On June 4, 2021, in connection with the private placement, FWTI issued 200,000 common shares (the "Advisory Shares") and 200,000 common share purchase warrants (the "Advisory Warrants") to Mackie Research Capital Corporation. Each Advisory Warrant entitled the holder to purchase one common share of FWTI at a price of \$1.00 per common share, for a period of 24 months following the date of issuance. The Advisory Shares and Advisory Warrants were converted at the Exchange Ratio at the closing of the Transaction, and as a result their fair value has been determined based on the value of the HWCC (Resulting Issuer) shares as that was determined to represent the most reliable measure of the share consideration.

The fair value of the Advisory Shares was determined to be \$0.20 per resulting issuer share based on the fair value at June 4, 2021. The fair value of the Advisory Warrants of \$123,000 was determined using the Black-Scholes pricing model.

Share issuance costs consist of the following:

Legal costs	\$ 119,761
Cash commission	377,600
Broker warrants issued	232,831
Advisory shares issued	200,000
Advisory warrants issued	 123,000
	\$ 1,053,192

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

- (b) On October 20, 2021, 7,724,999 HWCC shares were deemed to be exchanged for the shares of the Company in connection with the Transaction. The fair value of the HWCC shares was determined based on the historical trading price of HWCC which was determined to be the most reliable measure of the Transaction.
- (c) In connection with the Transaction, FWTI paid a \$165,480 cash finder's fee and issued 220,640 FWTI Units pursuant to an advisory agreement between FWTI and WD Capital Markets Inc. (the "Finder").
 - The allocation of the FWTI Unit between share capital and warrants was done based on the relative fair value of each of the components after applying the Exchange Ratio. The securities underlying FWTI Units were converted at the Exchange Ratio at the closing of the Transaction, and their fair value has been determined based on the value of the HWCC (Resulting Issuer) shares as that was determined to represent the most reliable measure of the share consideration. The fair value of the share capital was determined to be \$0.20. The fair value of the warrants was determined using the Black-Scholes pricing model. The relative fair value of the shares was determined to be \$174,306 and the relative fair value of the warrant was determined to be \$46,334.
- (d) Immediately prior to the closing of the Transaction, two series of FWTI convertible debentures were converted into 1,652,380 FWTI common shares, which were exchanged for 8,261,900 shares of the Company based on the Exchange Ratio.

Stock options:

The Company has a rolling stock option plan (the "Plan") that authorizes the Board of Directors to grant incentive stock options to directors, officers, consultants and employees, whereby a maximum of 10% of the issued common shares are reserved for issuance under the Plan. Under the Plan, the exercise price of each option may not be less than the market price of the shares of the Company at the date of grant. The maximum term for options granted under the Plan is five years.

The following table summarizes the movements of the stock options for the twelve months ended March 31, 2022:

	Number of options	Weighted average exercise price
Options outstanding at March 31, 2021	-	\$ -
Issued in reverse takeover	772,499	0.203
Granted	1,961,071	0.175
Options outstanding at March 31, 2022	2,733,570	\$ 0.183

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

On October 20, 2021, HWCC's 772,499 outstanding stock options were assumed in connection with the Transaction. The outstanding HWCC options were valued at \$53,901 using the Black-Scholes pricing model.

- a) On November 9, 2021, 1,338,571 stock options were granted in exchange for services provided. The stock options are exercisable at \$0.175 and expire on November 9, 2023. These stock options have a fair value of \$248,956 and vested immediately on the grant date.
- b) On November 9, 2021, 622,500 stock options were granted to certain employees and directors of the Company. The stock options are exercisable at \$0.175 and expire on November 9, 2026. These stock options have a fair value of \$82,228. Of the total options granted 33% of the stock options vested immediately on the grant date, 33% vest on the first anniversary of the grant date, and the remaining balance vests on the second anniversary of the grant date.

The fair value of the stock options was determined using the Black-Scholes pricing model.

As at March 31, 2022, \$34,678 in stock based compensation has been recognized in the consolidated statement of loss and comprehensive loss.

The following table provides additional information about the outstanding stock options as at March 31, 2022:

Grant Date	Expiry Date	Number of Stock Options Outstanding	Number of Stock Options Exercisable		xercise Price	Remaining Life (in years)
0		500 405	500.105	•		0.00
October 20, 2021	May 3, 2022	502,125	502,125	\$	0.200	0.09
October 20, 2021	November 6, 2022	270,374	270,374		0.210	0.60
November 9, 2021	November 9, 2023	1,338,571	1,338,571		0.175	1.61
November 9, 2021	November 9, 2026	622,500	207,499		0.175	4.61
		2,733,570	2,318,569	\$	0.183	1.43

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

Results of Operations

For the year ended March 31,

	,		,
	2022	2021	2020
Revenue	\$ 6,244	41,575	31,345
Expenses:			
General and administrative	2,001,842	589,473	691,676
Selling and marketing	133,938	22,656	90,993
Research and development	916,579	705,761	857,968
Listing expenses	1,143,481	-	-
Foreign exchange loss (gain)	(8,907)	187	3,167
	4,186,933	1,318,077	1,643,804
	(4,180,689)	(1,276,502)	(1,612,459)
Other expense (income):			
Amortization of deferred capital contributions	(99,266)	(210,294)	(256,319)
Operating grants	(26,581)	(223,033)	(154,862)
Investment tax credits	-		(228,984)
Finance income	(1,152)	(1,998)	(6,605)
Finance costs	111,908	389,822	103,572
Gain on debt settlement	-		212,556
Change in fair value of financial instruments	13,078	269,271	
	(2,013)	223,768	(330,642)
Net loss and comprehensive loss	\$ (4,178,676) \$	(1,500,270) \$	(1,281,817)
Basic/diluted loss per share*	\$ (0.05) \$	(0.03) \$	(0.03)
Weighted average number of basic common shares	77,872,756	54,000,000	50,525,000

^{*}Reflect the retrospective application of the 1:5 exchange ratio

Revenue:

Revenues for the year ended March 31, 2022 were \$6,244 compared to \$41,575 for the same period in 2021. The Company continues to focus on the development of new clients which require a long cycle time.

MD&A (Cont'd)
For the years ended March 31, 2022 and 2021

Expenses:

General and Administrative – general and administrative expenses as of the year ended March 31, 2022 were \$2,001,842 an increase of \$1,412,369 or 240% from the prior period primarily as a result of higher consulting, filing, and marketing consultant expenses related to the Transaction.

Selling and Marketing – selling and marketing expenses for the year ended March 31, 2022 were \$133,938 an increase of \$111,282 or 491% compared to the same period in 2021 primarily related to costs associated with marketing consultants engaged to promote FWTC.

Research and Development – research and development costs for the year ended March 31, 2022 were \$916,579, a \$210,818 or 30% increase from the same period in 2021 as a result higher developmental research fees partially offset by lower depreciation as some assets were fully depreciated.

Listing expenses – listing expenses for the year ended March 31, 2022 were \$1,143,481 compared to \$nil for the same period in 2021. These were non-cash and were incurred as part of closing the Transaction.

Foreign Exchange Loss/(Gain) – foreign exchange loss is a result of the changes in foreign currency amounts being settled through accounts payable. The payables are primarily related to tools and equipment purchased in USD. Foreign exchange loss for the year ended March 31, 2022 was a gain of \$8,907, an increase of \$9,094 over the same period in 2021.

Other Expense (Income):

Amortization of Deferred Capital Contributions - deferred capital contributions represent the unamortized and unspent balances of designated grants and funding received for the purchase of equipment. The amortization of capital contributions is recorded as income in the statement of loss and comprehensive loss. The amortization of deferred capital contributions for the year ended March 31, 2022 was income of \$99,266, a decrease of \$111,028 or 53% over the same period in 2021 as a result of no new funding being received for capital purchases in the past two years.

Operating Grants - operating grants for the year ended March 31, 2022 were \$26,581, a decrease of \$196,452 or 88% compared to the same period in 2021 as a result of minimal funding being available from the Canada Emergency Business Account loan and Industrial Research Assistance Program and Bioindustrial Innovation Canada grants.

Finance Income - finance income for the year ended March 31, 2022 was \$1,152, a decrease of \$846 over the same period in 2021 as the Company received interest on a tax refund in the prior period.

Finance Costs - finance costs for the year ended March 31, 2022 were \$111,908, a decrease of \$277,914 or 71% over the same period in 2021 primarily as a result of the repayment of \$500,000 of debentures and the conversion \$1.7 million of debentures to common shares in connection with the closing of the Transaction.

Change in Fair Value of Financial Instruments - change in fair value of financial instruments relates to the convertible debentures that are carried at fair value. For the year ended March 31, 2022 the change in fair value was \$13,079, a decrease of \$256,193 or 95% compared to the same period in 2021. For both periods,

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

this is primarily as a result of the change in the risk free rate, the settlement of the amount and the value of the debentures during these periods.

Net Loss and Earnings per Share:

The net loss and comprehensive loss for the year ended March 31, 2022 was \$4,178,676 compared to \$1,500,270 for the same period in 2021. On a per share basis this translated into a net loss per basic share of \$0.05 for the year ended March 31, 2022, compared to net loss per basic share of \$0.03 for the same period in 2021.

Total Assets and Liabilities:

	March 31, 2022	March 31, 2021
Assets		
Current assets	3,631,659	294,316
Property and equipment	925,547	803,447
	4,557,206	1,097,763
Liabilities and Shareholde		
Current liabilities	463,995	2,738,872
Deferred capital contributions	261,859	361,125
Government loan payable Loans payable	38,382 279,172	31,077 233,289
	1,043,408	3,364,363
Shareholders' Equity (Deficiency):		
Share capital	9,497,026	1,636,352
Warrants	1,760,865	-
Contributed surplus	2,635,705	2,298,170
Deficit	(10,379,798)	(6,201,122)
	3,513,798	(2,266,600)

Total assets were \$4,557,206 as of March 31, 2022, an increase of \$3,459,443 or 315% over the period ended March 31, 2021 primarily as a result of the addition of funds held in trust due to the brokered private placement offering Subscription Receipts and higher prepaids for communications consultants.

\$

4,557,206 \$

1,097,763

Current liabilities as of March 31, 2022 were \$463,995, a decrease of \$2,274,877 over the prior period ended March 31, 2021 primarily as a result of the payment of \$500,000 in debentures, the conversion of \$1,500,000 in debentures carried at \$1,482,63 to shares and the conversion of a warrant liability of \$230,880.

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

Long term liabilities as of March 31, 2022 were \$579,413, a decrease of \$46,078 or 7% primarily as a result of amortization of deferred capital contributions due to a depletion of contributions partially offset by higher loan payables due to accretion of interest.

Cash Flows:

	For the year ended March 31,			
	2022	2021		
Cash provided by (used in):				
Operating activities:				
Net loss	\$ (4,178,676) \$	(1,500,270)		
Items not involving cash	1,938,727	772,349		
Changes in non-cash operating working capital	(415,061)	528,198		
	(2,655,010)	(199,723)		
Financing activities	5,472,639	10,000		
Investing activities	47,504	-		
Increase (decrease) in cash	2,865,133	(189,723)		
Cash, beginning of year	147,236	336,959		
Cash, end of year	\$ 3,012,369 \$	147,236		

Net cash outflows from operating activities:

For the year ended March 31, 2022, net cash flows from operating activities were an outflow of \$2,655,010, an increase in outflows of \$2,455,827 compared to the year ended March 31, 2021. The increase was primarily due to a higher net loss as discussed above partially offset by non-cash listing expenses.

Net cash flows from financing activities:

Net cash flows from financing activities for the year ended March 31, 2022 were \$5,472,639, an increase of \$5,462,639 compared to the year ended March 31, 2021 primarily as a result of the proceeds from the sale of Subscription Receipts and, cash obtained from the Transaction partially offset by issuance costs and the repayment of the loans payable and debentures.

Net cash flows from investing activities:

Net cash outflows from investing activities for the year ended March 31, 2022 were \$47,504, an increase in outflows of \$47,504 compared to the year ended March 31, 2021 due to cash spent for capital equipment fully offset by funds obtained from the Transaction.

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

Quarterly Results:

	Three Months Ended							
_	Jun 20	Sep 20	Dec 20	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22
_	\$	\$	\$	\$	\$	\$	\$	\$
Revenue	-	5,988	34,453	1,316	-	600	5,644	-
Net loss/comprehensive loss	(270, 178)	(336,553)	(315,298)	(578,241)	(565,985)	(999,559)	(1,938,856)	(674,276)
Net cash (outflow) from operating activities	134,727	(164,943)	(141,357)	(28,150)	(90,506)	(97,578)	(2,052,629)	(414,297)
Weighted average number of shares (m)	54.0	54.0	54.0	54.0	54.0	56.2	94.9	105.6
Basic loss per share	(0.01)	(0.01)	(0.01)	(0.01)	(0.01)	(0.02)	(0.02)	(0.01)

Since early 2020, much of the Company's effort has been building a prototype and proving out its technology. Revenues were generated as part of the prove out process. Government grants were used to partially offset R&D costs.

In mid-2021, the Company embarked on the process of becoming public through the Transaction. The costs in preparation for the Transaction began in Q3 2021 which increased net and comprehensive losses, though an effort was made to conserve cash until the public listing. FWT become publicly listed in October 2021, resulting in listing costs of over \$2 million and substantially increasing operating losses.

Significant Projects:

In December 2021, FWTC began the building of a mobile commercial demonstration unit which can be placed on a customer's site to allow for a longer term (3-4 month) performance of the forward osmosis technology at industrial throughput that is not achievable in a laboratory setting. This is expected to be completed in July, 2022 at a cost of \$1.1 million.

Use of Proceeds:

USE OF FUNDS	<u>Planned</u>	Current Forecast	<u>Variance</u>	Explanation of Variance
Mobile Demo Unit	1,500,000	1,085,000	415,000	Lower than forecast
Research & Development	450,000	450,000	-	
Sales & Marketing	700,000	1,115,000	- 415,000	Additional investor research costs
Intellectual Property Filings	200,000	200,000	-	
SG&A	900,000	900,000	-	_
Total	3,750,000	3,750,000	-	_
Working Capital and Other Corporate Purposes	1,250,000			_
Total from Transaction	5,000,000			

The main focus for the next twelve months will be to launch the mobile demonstration unit and continue with business development efforts.

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

Material Breakdown of Expense:

General and administrative

	For the year ended March 31,			
	2022		2021	
General and administrative:				
Depreciation	\$ -	\$	1,101	
Office, administration and other	299,642		161,987	
Consulting, contracts and professional fees	1,332,875		227,451	
Salaries and benefits	334,647		198,934	
Stock based compensation	34,678		-	
	\$ 2,001,842	\$	589,473	

Consulting, contracts and professional fees of \$1,332,875 for the year ended March 31, 2022 are primarily as a result of higher consulting, filing, and marketing consultant expenses related to the Transaction.

Research and development

For the year ended March 31,

	2022	2021
Research and development	916,579	705,761

Research and development expense for the year ended March 31, 2022 of \$919, 579 is primarily related to engineering consulting, design and process development to support the development of the mobile commercial demonstration unit.

Property and equipment

Cost	Equipment	Computer hardware	Construction in progress	Total	
March 31, 2020 and 2021	\$ 2,076,254 \$	5,500	\$ -	\$	2,081,754
Additions	21,120	-	366,232		387,352
March 31, 2022	\$ 2,097,374 \$	5,500	\$ 366,232	\$	2,469,106

Construction in progress consists of the initial spend for the mobile demonstration unit which will has a total projected spend of \$1.1 million.

MD&A (Cont'd)
For the years ended March 31, 2022 and 2021

Outstanding Share Capital:

As of the date of this MD&A, the Company has outstanding share capital of:

Shares: 105,600,099 Warrants: 19,614,600 Options: 2,733,570

Off-Balance Sheet Arrangements:

There are no off-balance sheet arrangements.

Going Concern Risk:

This MD&A has been prepared on the basis of accounting principles applicable to a going concern. However, in common with many early-stage enterprises engaged in product commercialization, there is significant doubt about the appropriateness of the use of the going concern assumption because the Company has a history of losses and negative cash flows from operations.

The ability of the Company to continue as a going concern and realize its assets and discharge its liabilities in the normal course of business is dependent upon the continued support from its shareholders, and on its ability to achieve and maintain profitable operations in the future. The Company's ability to establish profitable operations in the future is dependent upon securing additional funding and financing arrangements. There can be no assurance that such events will occur.

The Company's financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern basis was not appropriate for these financial statements, then adjustments would be necessary to the carrying amount of assets, the reported revenue and expenses, and the balance sheet classifications used.

Financial Risks and Concentration of Risk:

(a) Currency risk:

The Company is exposed to financial risks as a result of exchange rate fluctuations and the volatility of these rates. In the normal course of business, the Company may purchase property and equipment denominated in U.S. dollars. The Company does not currently enter into forward contracts to mitigate this risk.

(b) Liquidity risk:

Liquidity risk is the risk that the Company will be unable to fulfill its obligations on a timely basis or at a reasonable cost. The Company manages its liquidity risk by monitoring its operating requirements. The Company has continued to incur losses and generate negative cash flows from operations. The Company prepares budgets and cash forecasts to ensure it has sufficient funds to fulfill its obligations.

The following table details the remaining contractual maturities at the end of the reporting period of the Company's financial liabilities, which are based on contractual undiscounted cash flows:

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

At March 31, 2022	Carrying amount	Total contractual cash flows	wit	Repayable hin 1 year or on demand	Repayable more than 1 year but less than 2 years	•	Repayable more than 2 ears but less than 5 years
Accounts payables and accrued liabilities Government loan payable Loan payable	\$ 463,995 38,382 279,172 781,549	\$ 463,995 45,000 300,000 808,995	\$	463,995 - - 463,995	\$ 45,000 - 45,000	\$	- 300,000 300,000
At March 31, 2021	Carrying amount	Total contractual cash flows	wit	Repayable hin 1 year or on demand	Repayable more than 1 year but less than 2 years	•	Repayable more than 2 ears but less than 5 years
Accounts payables and accrued liabilities Debentures Convertible Debentures Government loan payable Loan payable	\$ 525,356 500,000 1,482,636 31,077 233,289 2,772,358	\$ 525,356 540,000 1,224,000 45,000 300,000 2,634,356	\$	525,356 540,000 1,224,000 - - 2,289,356	\$ - - - 45,000 - 45,000	\$	- - - - 300,000 300,000

(c) Credit risk:

Credit risk refers to the risk that a counterparty may default on its contractual obligations, resulting in a financial loss. Substantially all of the Company's cash is deposited with financial institutions in Canada that are of high-credit quality to minimize credit risk exposure. The Company is exposed to credit risk with respect to accounts receivable. The Company performs ongoing credit evaluations of its customers and maintains provisions for potential credit losses.

(d) Capital risk management:

The Company's capital is composed of shareholder's equity and a shareholder loan. The Company's objective in managing its capital is to ensure it maintains capital ratios in order to supports its business. The Company manages its capital structure through regular reviews of financial information to ensure adjustments can be made to be in line with changes in the economic conditions and to maintain value for the shareholders.

(e) Measurement of fair value

The carrying value of cash, short-term investments, amounts receivable, and trade payables and accrued liabilities approximate their fair values due to their short-term to maturity. The convertible debentures and the warrant liability are measured at the fair value through profit and loss ("FVTPL").

During the reporting periods, there were no transfers between Level 1 and Level 2 fair value measurements.

MD&A (Cont'd)
For the years ended March 31, 2022 and 2021

Business Risks and Uncertainties

1. Key Personnel

FWT's success has depended and continues to depend upon its ability to attract and retain key management. The Company does not maintain key person life insurance policies on any employees. The Company will attempt to enhance its management and technical expertise by continuing to recruit qualified individuals who possess desired skills and experience in certain targeted areas. The Company's inability to retain employees and attract and retain sufficient additional employees or scientific and technical support resources could have a material adverse effect on the Company's business, results of operations, sales, cash flow or financial condition. Shortages in qualified personnel or the loss of key personnel could adversely affect the financial condition of the Company and results of operations of the business and could limit the Company's ability to develop and market its services and products. The loss of any of the Company's senior management or key employees could materially adversely affect the Company's ability to execute its business plan and strategy, and the Company may not be able to find adequate replacements on a timely basis, or at all.

2. Dependence on Suppliers and Skilled Labor

The ability of the Company to compete and grow will be dependent on it having access, at a reasonable cost and in a timely manner, to skilled labour and equipment. No assurances can be given that the Company will be successful in maintaining its required supply of skilled labour, equipment, parts and components. It is also possible that the final costs of any major equipment contemplated by the Company's capital expenditure program may be significantly greater than anticipated by the Company's management and may be greater than funds available to the Company, in which circumstance the Company may curtail, or extend the timeframes for completing, its capital expenditure plans. This could have an adverse effect on the financial results of the Company.

3. Rapid Technology Change

The Company operates in a competitive marketplace; there are no guarantees that the Company can maintain or expand its advantages. The Company invests significantly in the development of products and continually seeks to improve its current product offerings. The success of the Company continues to depend upon market acceptance of its new products, its existing products and its ability to refine and enhance current product lines.

4. Negative Cash Flow

The Company has incurred losses since its inception. The Company may not be able to achieve or maintain profitability and may continue to incur significant losses in the future.

5. Clients may Terminate Accounts

Clients may terminate their relationship with FWT at any time, subject to the terms of the contractual agreement between FWT and such clients.

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

6. Ongoing Costs and Obligations

The Company expects to incur significant ongoing costs and obligations related to its investment in infrastructure and growth and for regulatory compliance, which could have a material adverse impact on the Company's results of operations, financial condition and cash flows. In addition, future changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company's operations, increase compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company. The Company's efforts to grow the business may be costlier than expected, and FWT may not be able to increase revenue enough to offset any higher operating expenses. FWT may incur significant losses in the future for a number of reasons and unforeseen expenses, difficulties, complications and delays, and other unknown events. If FWT is unable to achieve and sustain profitability, the market price of the common shares may significantly decrease.

7. Additional Financing

The operation of FWT's facilities and business are capital intensive. In order to execute the anticipated growth strategy, FWT may require additional equity and/or debt financing to support ongoing operations, to undertake capital expenditures or to undertake acquisitions or other business combination transactions. There can be no assurance that additional financing will be available to FWT when needed or on terms which are acceptable.

The Company's inability to raise financing to support on-going operations or to fund capital expenditures or acquisitions could limit FWT's growth and may have a material adverse effect upon future profitability. FWT may require additional financing to fund its operations to the point where it is generating positive cash flows.

If additional funds are raised through further issuances of equity or convertible debt securities existing shareholders could suffer significant dilution, and any new equity securities issued could have rights, preferences and privileges superior to those of holders of common shares. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for FWT to obtain additional capital and to pursue business opportunities, including potential acquisitions.

8. Change of Control on Material Contracts

It is possible that material contracts to which FWT is a party may be subject to review or termination upon a change of control. While FWT is not aware of any counterparty which may wish to terminate a material contract, should any such contracts be terminated, FWT will lose the benefit of the contract as well as subsequent usage or subscription revenue associated with that contract depending on the services rendered.

9. Success of Quality Control Systems

The quality and safety of the Company's products and services are critical to the success of its business and operations. As such, it is imperative that the Company's (and its service providers') quality control systems operate effectively and successfully. Quality control systems can be

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

negatively impacted by the design of the quality control systems, the quality training program, and adherence by employees to quality control guidelines. Although the Company strives to ensure that all its customers and partners have implemented and adhere to high caliber quality control systems, any significant failure or deterioration of such quality control systems could have a material adverse effect on the Company's business and operating results.

10. Management of Growth

The Company may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls. The ability of the Company to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of the Company to deal with this growth may have a material adverse effect on the Company's business, financial condition, results of operations and prospects.

11. Reputational Harm

Damage to the Company's reputation can be the result of the actual or perceived occurrence of any number of events, and could include any negative publicity, whether true or not. The increased usage of social media and other web-based tools used to generate, publish, and discuss usergenerated content and to connect with other users has made it increasingly easier for individuals and groups to communicate and share opinions and views regarding the Company and its activities, whether true or not. Although the Company believes that it operates in a manner that is respectful to all stakeholders and that it takes pride in protecting its image and reputation, the Company does not ultimately have direct control over how it is perceived by others. Reputation loss may result in decreased investor confidence, increased challenges in developing and maintaining community relations and an impediment to the Company's overall ability to advance its projects, thereby having a material adverse impact on financial performance, financial condition, cash flows and growth prospects.

12. Legal Proceedings

In the course of the Company's business, the Company may from time to time have access to confidential or proprietary information of third parties, and these parties could bring a claim against the Company asserting that it has misappropriated their technologies and improperly incorporated such technologies into its products. The Company has implemented processes and internal protocols to safeguard such third-party's proprietary rights in order to mitigate such risks but there is no guarantee that such processes and protocols will be successful in all cases. Due to these factors, there remains a constant risk of intellectual property litigation affecting the Company's business. In the future, the Company may be made a party to litigation involving intellectual property matters and such actions, if determined adversely, could have a material adverse effect on the Company.

13. Epidemics and Pandemics

The Company faces risks related to health epidemics, pandemics and other outbreaks of communicable diseases, which could significantly disrupt its operations and may materially and adversely affect its business and financial conditions. The Company's business could be adversely

MD&A (Cont'd)

For the years ended March 31, 2022 and 2021

impacted by the effects of the COVID-19 pandemic or other epidemics and/or pandemics. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic. The extent to which COVID-19 impacts the Company's business, including its operations and the market for its securities, will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic (including recommendations from public health officials).

Specifically, activities related to fabrication, field trials, installation, and commissioning of equipment may be delayed as these activities require different groups of skill sets and those teams may not be able to be on-site simultaneously. Other activities such as project planning with clients for these activities may also be impacted due to on-going person-to person contact restrictions. Internally at FWTC sites, restricted interactions with staff members may delay on-going scientific and engineering work.

In addition, the COVID-19 pandemic represents a widespread global health crisis that could adversely affect global economies and financial markets resulting in an economic downturn that could have an adverse effect on the Company. If the global response to contain a pandemic or similar event escalates or is unsuccessful, such events may have a material adverse effect on our business, financial condition, results of operations, and cash flows.

No matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the Company, the results of those operations or the state of affairs of the Company or economic entity in subsequent financial periods.

Disclosure Controls and Procedures

Disclosure controls and procedures ("DC&P") are intended to provide reasonable assurance that material information is gathered and reported to senior management to permit timely decisions regarding public disclosure. Internal controls over financial reporting ("ICFR") are intended to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with IFRS accounting principles.

TSX Venture Exchange-listed companies are not required to provide representations in their annual and interim filings relating to the establishment and maintenance of DC&P and ICFR, as defined in Multinational Instrument 52- 109. In particular, the CEO and CFO certifying officers do not make any representations relating to the establishment and maintenance of (a) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation, and (b) processes to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with the issuer's GAAP.

Additional information related to the Company can be found on the Company's profile on www.sedar.com